TVRD Tvardi Therapeutics, Inc.
Company Analysis
Latest News
🟢 Tvardi Therapeutics is trading 9.43% up in pre-market
Tvardi Therapeutics is trading at $1.39, up 9.43% in pre-market versus the September 25 close of $1.27; no confirmed catalyst was identified. - No company...
🟢 Tvardi Therapeutics is trading 11.79% up today after TTI-101 prevented polyps and adenocarcinomas in mice
Tvardi Therapeutics is trading at $1.19, up 11.79%, on September 25, 2026, following preclinical findings that oral TTI-101 prevented polyps and...
🟢 Tvardi Therapeutics is trading 6.13% up today after TTI-101 prevented colon polyps in mice
Tvardi Therapeutics is trading 6.13% higher at $1.12 after investors responded to September 24 preclinical data on TTI-101, its oral STAT3 inhibitor. - The...
Tvardi's Mouse Data Sparks a 9% Bounce, but Can a Cash-Strapped Micro-Cap Survive Long Enough to Prove Its Science?
Shares of Tvardi Therapeutics shifted sharply higher Thursday, rising 9.4% to $1.16, after the company published preclinical data showing its oral drug...
🟢 Tvardi Therapeutics is trading 9.43% up in pre-market after positive preclinical STAT3-inhibitor data in ulcerative colitis
Tvardi Therapeutics is trading 9.43% up at $1.16 in pre-market after announcing positive preclinical data for its STAT3 inhibitors in ulcerative colitis. -...
🟢 Tvardi Therapeutics is trading 5.66% up in after-hours trading after preclinical data showed TTI-101 prevented tumors
Tvardi Therapeutics is trading 5.66% higher at $1.12 in after-hours trading after announcing preclinical data supporting its STAT3 inhibitors in ulcerative...
🔴 Tvardi Therapeutics is trading 12.88% down today amid biotech weakness, elevated yields and inflation concerns
Tvardi Therapeutics is trading 12.88% lower at $1.15, tracking biotechnology weakness, elevated Treasury yields, inflation concerns and broader risk-off...
🔴 Tvardi Therapeutics is trading 6.1% down today amid broader biotech and macro pressure
Tvardi Therapeutics is trading 6.1% down at $1.24, amid broader biotech and macro pressure. - Shares declined 15.92% to $1.32 on September 23; no negative...
🟢 Tvardi Therapeutics is trading 6.06% up in after-hours trading
Tvardi Therapeutics is trading 6.06% higher at $1.40 after hours, with no confirmed company-specific catalyst identified. - The stock closed at $1.32 on...
🔴 Tvardi Therapeutics is trading 10.83% down today as crude prices and Treasury yields rise
Tvardi Therapeutics is trading 10.83% lower at $1.40 as broader markets weaken amid rising crude oil prices, inflation concerns and higher Treasury yields. -...
🟢 Tvardi Therapeutics is trading 5.6% up today amid broader risk-on sentiment
Tvardi Therapeutics is trading at $1.70 (+5.59%) amid broader risk-on sentiment. - No clearly reported company-specific announcement emerged on September 22,...
🔴 Tvardi Therapeutics is trading 5.8% down today as specific catalyst remains unclear
Tvardi Therapeutics is trading 5.8% down at $1.63, despite biotechnology and major U.S. indexes moving higher; the specific catalyst remains unclear. - The...
🟢 Tvardi Therapeutics is trading 6.3% up today ahead of its September 14, 2026 presentation
Tvardi Therapeutics is trading at $1.99 (+6.26%) ahead of its September 14, 2026 presentation at the H.C. Wainwright Global Investment Conference. • The...
🟢 Tvardi Therapeutics is trading 5.18% up today as major U.S. indexes rise
Tvardi Therapeutics is trading 5.18% higher at $1.93, moving alongside a broadly stronger U.S. market. - The S&P 500, Nasdaq Composite, and Dow Jones...
🟢 Tvardi Therapeutics is trading 6% up today as biotech ETF XBI gains 2.75%
Tvardi Therapeutics is trading at $1.85, up 6.02%, in a move that appears primarily sector-driven, with biotech ETF XBI up 2.75% during regular trading. - No...
🟢 Tvardi Therapeutics is trading 6.81% up today in pre-market — catalyst remains unclear
Tvardi Therapeutics is trading at $1.86 (+6.81%) in pre-market, but the catalyst is unclear. - No clear company-specific announcement dated September 2, 2026...